Governments Innovation News Pharma & Biotechnology Policy

Fujifilm COVID-19 drug research spills into June, dashing hopes of quick approval

Fujifilm Holdings Corp will continue research on Avigan into June, Japan’s government said on Tuesday, effectively dashing hopes by Prime Minister Shinzo Abe that the drug would be approved as a COVID-19 treatment this month.

Abe had said he hoped the drug would be approved in May if its efficacy and safety could be confirmed.

“The company will continue research into next month or so, and if an application for approval is received from the company, it will be promptly reviewed,” Chief Cabinet Secretary Yoshihide Suga said at a regular briefing when asked about Avigan.

Suga said trials of a coronavirus vaccine could begin as early as July, raising expectations about a candidate developed by Osaka University and biopharmaceutical firm AnGes Inc.

Kyodo News reported late on Monday the government had given up on Avigan’s May timeline. Last week, the news agency said an interim study showed no clear evidence of the drug’s efficacy in COVID-19 cases.

“While we continue with the ongoing clinical trials, Fujifilm will remain in close contact with the regulatory authority and work toward the application for approval at the earliest possible timing,” Fujifilm spokeswoman Kana Matsumoto said on Tuesday.

Read More

Meeta Ramnani
Meeta Ramnani
Meeta develops credible content about various markets based on deep research, opinions from experts and inputs from industry leaders. As the managing editor at Smart Industry News, she assures that every piece of news and article adds to the knowledge of decision makers. An avid bike rider, Meeta, is a postgraduate from Indian Institute of Journalism and New Media (IIJNM) Bangalore, where her specialization was Business Journalism. She carries experience from mainstream print media including The Times Group and Sakal Media Group.